Biocogniv & Research Partners Detail First Artificial Intelligence Tool to Help Laboratories Rule-Out COVID-19

Biocogniv & Research Partners Detail First Artificial Intelligence Tool to Help Laboratories Rule-Out COVID-19




Biocogniv & Research Partners Detail First Artificial Intelligence Tool to Help Laboratories Rule-Out COVID-19

AI software uses routine blood work to assist clinical labs with COVID testing shortage

BURLINGTON, Vt.–(BUSINESS WIRE)–#AI–Hospital-based laboratories and doctors at the front line of the COVID-19 pandemic might soon add artificial intelligence to their testing toolkit. A recent study conducted with collaborators from the University of Vermont and Cedars-Sinai describes the performance of Biocogniv’s new AI-COVID™ software. The team found high accuracy in predicting the probability of COVID-19 infection using routine blood tests, which can help hospitals reduce the number of patients referred for scarce PCR testing.

Their study in the Journal of Medical Internet Research is available online at https://www.jmir.org/2020/12/e24048

“Nine months into this pandemic, we now have a better understanding of how to care for patients with COVID-19,” says lead author and University of Vermont Assistant Professor Timothy Plante, MD, “but there’s still a big bottleneck in COVID-19 diagnosis with PCR testing.”

PCR testing is the current standard diagnostic for COVID-19, and requires specific sampling, like a nasal swab, and specialized laboratory equipment to run.

Biocogniv Chief Operating Officer Tanya Kanigan, PhD, says, “According to data from over 100 US hospitals, the national average turnaround time for COVID-19 tests ordered in emergency rooms is above 24 hours, far from the targeted one-hour turnaround.”

Complete Blood Count and Complete Metabolic Panels are common laboratory tests ordered by emergency departments and have a rapid turnaround time. These tests provide insight into the immune system, electrolytes, kidney, and liver. The researchers were able to train a model that analyzes changes in these routine tests and assigns a probability of the patient being COVID-19 negative with high accuracy.

“AI-COVID takes seconds to generate its informative result once these blood tests return, which can then be incorporated by the laboratory into its own test interpretation,” says Jennifer Joe, MD, an emergency physician in Boston, Mass. and Biocogniv’s Chief Medical Officer. “In an efficient emergency department that prioritizes these routine blood tests, the door-to-result time could be under an hour.”

Cedars-Sinai pulmonary and internal medicine specialist Victor Tapson, MD, says such assistive tools that help physicians rule out possible diagnoses are familiar in emergency medicine.

“For example, a low D-dimer blood test can help us rule out clots in certain patients, allowing providers to skip expensive, often time-consuming diagnostics such as chest CT scans,” says Dr. Tapson.

The Biocogniv team believes a secondary benefit of laboratories incorporating AI-COVID might be reduced time for traditional PCR results.

“With the help of AI-COVID, laboratories might relieve some of the testing bottleneck by helping providers better allocate rapid PCR testing for patients who really need it,” says Dr. Joe.

The AI-COVID model was validated on real world data from Cedars-Sinai as well as on data from geographically and demographically diverse patient encounters from 22 US hospitals, achieving an area under the curve (or AUC) of 0.91 out of 1.00.

“This enables the model to achieve a high sensitivity of 95% while maintaining moderate specificity of 49%, which is very similar to the performance of other commonly used rule-out tests,” says Biocogniv Chief Scientific Officer George Hauser, MD, a pathologist.

Biocogniv CEO Artur Adib, PhD, says, “I’m honored to have such an impressive team of medical scientists from the University of Vermont and Cedars-Sinai as collaborators in validating this timely model. AI has progressed considerably; the time is now to leverage this powerful tool for new healthcare breakthroughs, and we’re glad to direct it to help hospital laboratories and providers combat the current COVID-19 crisis.”

About Biocogniv

Biocogniv, Inc, located in South Burlington, Vermont, is a privately held, biotechnology company developing AI-powered diagnostic software for hospitals and healthcare systems. Using cutting edge artificial intelligence modeling, Biocogniv’s flagship product is AI-COVIDTM, while also developing a strong pipeline of new targets, with funding from the National Science Foundation, the National Institutes of Health, and the prestigious startup accelerator Y Combinator. Learn more here: https://www.biocogniv.com/

About the University of Vermont

Since 1791, the University of Vermont has worked to move humankind forward. UVM’s strengths align with the most pressing needs of our time: the health of our societies and the health of our environment. Our size—large enough to offer a breadth of ideas, resources, and opportunities, yet intimate enough to enable close faculty-student mentorship across all levels of study—allows us to pursue these interconnected issues through cross-disciplinary research and collaboration. Providing an unparalleled educational experience for our students, and ensuring their success, are at the core of what we do. As one of the nation’s first land grant universities, UVM advances Vermont—and the broader society—through the discovery and application of new knowledge.

About Cedars-Sinai

Cedars-Sinai is a leader in providing high-quality healthcare encompassing primary care, specialized medicine and research. Since 1902, Cedars-Sinai has evolved to meet the needs of one of the most diverse regions in the nation, setting standards in quality and innovative patient care, research, teaching and community service. Today, Cedars-Sinai is known for its national leadership in transforming healthcare for the benefit of patients. Cedars-Sinai impacts the future of healthcare by developing new approaches to treatment and educating tomorrow’s health.

Contacts

Jennifer Joe, Biocogniv

Phone: (601) 667-9470

Email: jen@biocogniv.com

Jennifer Nachbur, Larner College of Medicine at the University of Vermont

Phone: (802) 338-8316

Email: jennifer.nachbur@med.uvm.edu

Laura Coverson, Cedars-Sinai Communications

Phone: 310-562-1112

Email: laura.coverson@cshs.org